DOI:
10.1055/s-00000009
American Journal of Perinatology
LinksClose Window
References
Sanchez-Luna M, Burgos-Pol R, Oyagüez I. , et al.
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
BMC Infect Dis 2017;
17 (01) 687
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.